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Abstract
Background: The potential role of adjunctive anti-inflammatory therapy to enhance tuberculosis (TB) treatment has
recently received increasing interest. There is, therefore, a need to broadly examine current host-directed therapies
(HDTs) that could accelerate treatment response and improve TB outcomes.
Methods: This systematic review and meta-analysis included randomised controlled trials of vitamin D and other
HDT agents in patients receiving antibiotic treatment for pulmonary TB. Sputum smear conversion rate at 4–8
weeks was the primary outcome. Secondary outcomes included blood indices associated with infectivity and
inflammation, chest radiology and incidence of adverse events.
Results: Fifty-five studies were screened for eligibility after the initial search, which yielded more than 1000 records.
Of the 2540 participants in the 15 trials included in the meta-analysis, 1898 (74.7%) were male, and the age at entry
ranged from 18 to 70 years. There was a 38% significantly (RR 1.38, 95% CI = 1.03–1.84) increased sputum smear
negativity in patients administered with vitamin D in addition to standard TB treatment than those receiving only
the TB treatment. Patients treated with other HDT anti-inflammatory agents in addition to TB treatment also had a
29% significantly increased sputum smear conversion rate (RR 1.29, 95% CI = 1.09–1.563). Lymphocyte to monocyte
ratio was significantly higher in the vitamin D treatment groups compared to the controls (3.52 vs 2.70, 95% CI for
difference 0.16–1.11, p = 0.009) and (adjusted mean difference 0.4, 95% CI 0.2 -- 0.6; p = 0.001); whilst tumour
necrosis factor-alpha (TNF-α) showed a trend towards a reduction in prednisolone (p < 0.001) and pentoxifylline
(p = 0.27) treatment groups. Vitamin D and N-acetylcysteine also accelerated radiographic resolution in treatment
compared to placebo at 8 weeks. No differences were observed in the occurrence of adverse events among all HDT
treatments.
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Conclusions: Vitamin D and other anti-inflammatory HDT medications used as adjunct TB treatment may be well
tolerated and effective. They significantly improved sputum smear conversion rate and chest radiological
appearance, and also exhibited an inflammation resolution effect.
Keywords: Adjunctive treatment, Anti-inflammatory agents, Host-directed therapy, Sputum conversion rate,
Systematic review & meta-analysis, Tuberculosis
Background
According to the World Health Organization, in 2017,
mortality from TB and TB-related deaths stood at 1.6
million, making TB the leading cause of death from a
single infectious agent worldwide, surpassing HIV/AIDS
[1]. Despite the decrease in numbers of TB deaths by
22% between 2000 and 2015 and that the incidence rate
continues to fall globally, the cost of TB treatment is still
high. About US$ 10.4 billion was required in low- and
middle-income countries to successfully continue with
the Global Plan to End TB 2016–2020 by The Stop TB
Partnership in 2018 [1].
Even though multiple antibiotic therapies administered
for 6 months are used to prevent the development of
drug resistance, the prolonged treatment duration,
coupled with the toxicity of the drugs, contributes to pa-
tient non-compliance [2, 3]. This can contribute to the
development of drug-resistant Mycobacteria tuberculosis
(Mtb), multi-drug-resistant (MDR) and extensive drug-
resistant (XDR) strains [4]. Host-directed therapy (HDT)
is an emerging concept in the treatment of TB, aimed at
directly modulating host cell functions, and is adminis-
tered in addition to antimicrobial treatment. Thus, the de-
velopment of drug resistance by Mtb may be reduced or
even avoided and better control of TB may be achieved [5,
6]. Functionally, HDT agents improve the antimicrobial
activities of host immune cells and limit inflammation and
tissue damage associated with TB [2, 7, 8].
Current drug regimens are mainly directed at various
targets on the Mtb bacillus [9, 10]; this means that even
after cure, TB patients are at risk of residual damage due
to inflammatory effects (post TB fibrosis and bronchiec-
tasis) [11]. Thus, supplementing anti-TB drug treatment
with host immune modulators may lead to shorter treat-
ment time, reduced lung damage, lower risk of relapse
or reinfection and also improvement of other clinical
outcomes [2, 10, 12–14].
The role of anti-inflammatory agents such as vitamin
D, phenylbutyrate, prednisolone and others have been
studied as HDT in human randomised control trials
(RCTs) with varied success [15–18]. Potential advanta-
geous functions that were identified, were to accelerate
the resolution of the inflammatory responses and to im-
prove other clinical outcomes associated with increased
risk of mortality [19]. The addition of these agents to the
therapy of pulmonary TB (PTB) was shown to signifi-
cantly accelerate sputum culture and/or smear conver-
sion rates, as well as clinical and radiographic
improvement, even though some yielded conflicting re-
sults [14, 20, 21].
In addition to their anti-inflammatory functions, HDT
may also provide other immune-modulating advantages.
Vitamin D (cholecalciferol-D3) is a known immune
modulator in TB, associated with cathelicidin-mediated
killing of mycobacterium [22, 23]. It has also been shown
to suppress NF-κB signalling pathways, expression of
matrix metalloproteinases (MMPs), and pro-inflammatory
cytokines and chemokines, thus accelerating the reso-
lution of inflammation [19]. Prednisone is a glucocorticoid
receptor antagonist that has the ability to downregulate
the production of pro-inflammatory cytokines such as
tumour necrosis factor (TNF) [24]. Recombinant human
interleukin, used as HDT, also enhances both the bacterial
clearance and immune response when administered twice
daily for 30 days [25]. N-acetylcysteine, another HDT mol-
ecule, effectively increases glutathione (GSH), which is
usually low in TB patients due to oxidative stress [26, 27].
Increased levels of GSH have been demonstrated to play a
positive role in phagocytosis, T-cell activation responses
and balancing in TB [28]. In human monocyte-derived
macrophage cell lines, recombinant human granulocyte-
macrophage colony-stimulating factor, which has cytokine
regulatory abilities, was observed to reduce Mycobacter-
ium growth, indicating its potential use as adjunct TB
treatment [29]. All this evidence supports the potential
use of HDT molecules to enhance TB treatment.
Currently, most meta-analyses conducted in the area
of HDT in TB are on vitamin D, and results seem to
suggest that it does not influence the time to sputum
culture and/or smear conversion [6, 30–32]. However,
one meta-analysis indicated that vitamin D accelerated
sputum culture conversion rate in patients with MDR
pulmonary TB [6]. Other anti-inflammatory agents, such
as prednisolone, also accelerated the sputum culture
conversion when used as HDT in pulmonary TB [17].
Considering that there are other agents used as HDTs, it
would be prudent to consider effects of these agents in
addition to vitamin D. Therefore, the present meta-
analysis was conducted to determine and estimate the
overall efficacy and safety of vitamin D and all other
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anti-inflammatory agents that have been used as adjunct
treatment in patients with TB, namely recombinant
human interleukin, prednisolone, pentoxifylline, N-
acetylcysteine and recombinant human granulocyte-
macrophage colony-stimulating factor. The efficacy and
safety of HDT agents were determined in relation to the
administered dosages. The analysis focused on smear
status as the primary outcome between 4 and 8 weeks of
treatment, considering the role of this marker as an indi-
cator of sterilizing activity [33] and as a predictor of
relapse risk [34, 35].
Methods
The review process and findings are reported according to
– and are consistent with – the PRISMA guidelines [36].
Eligibility (inclusion and exclusion criteria)
Eligibility of included studies was based on the following
criteria: 1) double-blind placebo-controlled RCTs, 2) tri-
als that were conducted in newly diagnosed PTB pa-
tients who were on initial anti-tuberculosis treatment
with sputum smear-positive for acid-fast bacilli or cul-
ture positive for Mtb at baseline, 3) the HDT agent was
used alone as an adjunct to standard anti-TB treatment,
4) trials were conducted in patients aged ≥18 years, 5)
treatment outcome measured between 4 and 8 weeks,
and 6) trials reporting the sputum smear or culture con-
version rate (proportion of participants with sputum
smear or culture conversion from positive to negative).
Furthermore, trials in which a factorial design was used
to investigate the effects of other therapies alongside the
anti-inflammatory therapy of interest (such that they
could be isolated) were also included. Trials conducted
in children or adolescents; single-blinded RCTs, non-
PTB, controlled experiments that were not randomised
(quasi-experimental studies) and open-label trials that
were not blinded, were excluded.
Search strategies
In this meta-analysis, two authors searched Medline
(Additional file 2), Cochrane Central Register of Con-
trolled Trials, embase, Web of Science and Google
scholar for trials, using the keywords “pulmonary tuber-
culosis” or “tuberculoses”, “anti-inflammatory agents”
and “host-directed-therapeutics”, with no limitations in
the publication type, language or period. The detailed
search string was as follows: Tuberculosis [MeSH
Terms] OR tuberculoses [MeSH Terms] OR Mycobac-
terium tuberculosis [MeSH Terms] AND Mycobacterium
tuberculoses [MeSH Terms] OR pulmonary tuberculosis
[MeSH Terms] OR pulmonary tuberculoses [MeSH
Terms] OR adjunctive immunotherapy in tuberculosis
[MeSH Terms] OR adjunctive immunotherapy in tuber-
culoses [MeSH Terms] OR adjunct tuberculosis
treatment [MeSH Terms] AND adjunct tuberculoses
treatment [MeSH Terms] OR host-directed-therapeutics
in tuberculosis [MeSH Terms] OR host-directed-
therapeutics in tuberculoses [MeSH Terms] OR anti-
tubercular agent [MeSH Terms] OR anti-inflammatory
agents [MeSH Terms] AND sputum smear conversion
[MeSH Terms] OR sputum culture conversion [MeSH
Terms] OR immune inflammatory response [MeSH
Terms] OR anti-inflammatory response [MeSH Terms]
OR inflammatory response [MeSH Terms] AND immu-
nomodulatory regulators [MeSH Terms] OR immuno
modulators [MeSH Terms] OR human [MeSH Terms]
OR human subjects [MeSH Terms] OR patients [MeSH
Terms] AND adults [MeSH Terms] AND randomised
control trials [MeSH Terms]. The database search was
from inception up to and including November 2019 and
was regularly updated. The reference or citation listed in
each identified article was also reviewed for potentially
relevant studies. These searches were supplemented by
searches of review articles and reference lists of trial
publications. When full-length articles were not available
from the databases, these were requested from the au-
thors. Four authors then determined which studies met
the eligibility criteria.
Data extraction and quality assessment
Four authors were involved in data extraction and qual-
ity assessment. Two authors independently performed
the initial extraction of data.
Data relating to the following study characteristics
were collected: authors, publication year, trial registra-
tion number, study setting, mode of anti-TB therapy ad-
ministration, details of adjunctive therapies being
evaluated in each trial (type, dose and route of treat-
ment) and primary study outcome. Baseline characteris-
tics of trial participant data were extracted for the
following variables: age, sex ratio, body mass index
(BMI), mid-upper arm circumference (MUAC), number
of participants randomised and those included, interven-
tion treatment duration and follow-up period, HIV sta-
tus, proportion with MDR-TB, extent of disease on
baseline chest radiograph (as measured by the propor-
tion of zones involved and the presence or absence of
cavitation), TB score, C-reactive protein (CRP), erythro-
cyte sedimentation rate (ESR), other blood indices, ad-
verse effects and mortality in a standard form as
recommended by Cochrane [37, 38]. Follow-up data
after 4–8 weeks of initiating antimicrobial and adjunct
treatment were also extracted, namely sputum smear
and culture status to estimate conversion rates, time
from initiation of antibiotic treatment to stable sputum
smear/culture conversion (the date of stable smear/cul-
ture conversion being estimated as the mid-point be-
tween the date of the last positive sputum smear/culture
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and the date of the first negative sputum smear/culture
thereafter); TB score, chest radiography, weight gain,
BMI, MUAC, CRP, ESR and other blood indices, as well
as adverse effects and mortality. For any missing infor-
mation, corresponding authors were contacted by email.
Three items were used to assess the methodological
quality of each included study, based on the Jadad scale
[39], which includes criteria of randomisation, blinding,
and addressing the problem of incomplete outcome data
(withdrawals and dropouts). The other two authors were
consulted to solve any disagreement on study selection,
data extraction, or quality assessment.
Definition of outcome measures
The primary and secondary outcome measures of the
meta-analysis comprised of efficacy assessment and
safety evaluation, respectively. The primary outcome was
sputum smear conversion rate, estimated as the percent-
age of smear-positive PTB (PTB+) cases registered in a
specified period that converted to smear-negative status
[40]. Secondary outcomes included sputum smear and
culture time to conversion, sputum culture conversion
rate, TB score, chest radiography, weight gain, BMI,
MUAC, CRP, ESR, other blood indices associated with
infectivity and inflammation (total white blood cells,
lymphocytes, neutrophils, monocytes, interferon gamma
(IFN-γ), and TNF-α), incidence of potential adverse re-
actions attributable to the study intervention agents and
all-cause mortality. These outcome measures are consid-
ered very relevant in TB disease progression and treat-
ment success.
Risk of bias across and within individual studies
Risk of bias assessment was conducted using the
Cochrane Collaboration Risk of Bias tool [37], consider-
ing the following parameters: sequence generation, allo-
cation concealment, blinding of participants, personnel
and outcome assessors, completeness of outcome data,
evidence of selective outcome reporting, and other po-
tential threats to validity. The Cochrane risk of bias tool
was used for the assessment of risk of bias in estimating
the study outcomes. The selective reporting within stud-
ies was assessed by answering whether the results were
fully reported, as the study was pre-specified (for ex-
ample, if all the results were reported at all follow-up
time points). For the primary analysis, the likelihood of
publication bias was investigated through the construc-
tion of a funnel plot and Egger’s test [41, 42]. Study
quality, in this case, was assessed independently by three
authors. Discrepancies were resolved by a fourth author.
Statistical methods
Meta-analysis of sputum smear conversion rate was con-
ducted using both random and fixed effect methods,
resulting in conversion hazard of the treatment group
with respect to the control group. Study weights re-
ported on the forest plots were derived from the random
effect analysis and were computed as wi = 1/(si
2 + t2)
with si
2 being the variance estimate from the i-th study
and t2 representing the overall variance. Standard errors
were computed as di/1.96 where di = max [(log (upper
95% confidence interval bound)-log (RRi); (log (RRi)-log
(lower 95% bound)].
Heterogeneity between studies was reported by means
of Cochrane Q test and I2 statistic [43]. When relevant
heterogeneity was detected (significant Cochrane Q test
and/or I2 > 50%), stratification and study exclusion were
conducted to identify its source. Publication bias was
assessed by means of funnel plot visual inspection and
Egger’s test [42]. Influence analysis, excluding one study
at a time, was conducted to assess robustness of results.
Statistical analysis was conducted using STATA, vers
15. Meta-analysis was performed using the metan func-
tion. Funnel plots, Egger’s test and influence analyses
were performed using the metafunnel, metabias and the
metainf functions, respectively. P value less than 0.05
was considered statistically significant.
Results
Description and quality assessment of included studies
The initial search yielded more than 1000 records (Add-
itional file 1). After the initial screening and duplicates
were removed, the remaining 55 unique studies identi-
fied were further screened for eligibility. Out of the 18
full-text articles identified and assessed for eligibility, 15
studies met the inclusion criteria of this meta-analysis.
Some reasons for excluding articles, were that the ad-
junct treatments used could not be isolated and some of
the articles were sub-studies of an article that was
already included. Fifteen articles were included in the
qualitative, whereas only 11 in the final quantitative syn-
thesis due to the unavailability of data from authors. The
detailed literature search and selection process is shown
in Fig. 1. The clinical trials were conducted in 12 coun-
tries and most of them were registered as described in
Table 1. Ten studies investigated the effect of vitamin D
[14–16, 18, 20, 21, 23, 44–46] as adjunct HDT agent,
while five studies used either recombinant human inter-
leukin [25], prednisolone [47], pentoxifylline [48], N-
acetylcysteine [49] or recombinant human granulocyte-
macrophage colony-stimulating factor [50]. Out of the
fifteen studies, thirteen studies used two-arm parallel de-
signs to investigate the effects of only one HDT treat-
ment [14–16, 21, 23, 25, 44–50]. Two studies included
L-arginine [20] and phenylbutyrate [18] concurrently
with vitamin D as HDT in a factorial design such that
they could be isolated. The treatments were adminis-
tered either by oral [15, 16, 18, 20, 21, 44–49],
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intramuscular [14, 23], intradermal [25] or subcutaneous
[50] routes. Apart from three studies [15, 16, 21], all
others followed the standard anti-TB therapy regime of
2 months of isoniazid, rifampicin, pyrazinamide, etham-
butol (HRZE), then 4 months of rifampicin and isoniazid
(RH) (Table 1). All studies included sputum smear and/
or culture conversion as a primary (or co-primary) or
secondary outcome measure. The following studies re-
ported these as primary outcomes: sputum culture con-
version rate [15, 16, 18, 20, 21, 25, 46], sputum smear
conversion rate [23, 44, 49], TB clinical scores [18, 20,
23, 45], chest radiograph resolution [14], weight gain
[14], treatment safety [47], treatment tolerance [50] and
treatment effect [48] (Table 2). According to the Jadad
scale, all the trials included in the meta-analysis were
considered high-quality studies as shown in supplemen-
tary Table 1 (Jadad score 3–5). All trials achieved the
maximum quality score of 5, except two studies which
scored 3 [44] and 4 [50] on the scale. Details of the qual-
ity assessment are provided in supplementary Table 1
(Additional file 2).
Study participants characteristics
A total of 2728 randomised participants from 15 studies
fulfilled the eligibility criteria, of which 2540 were in-
cluded in the final analysis. One thousand two hundred
Fig. 1 PRISMA flow diagram of study selection and inclusion process. CENTRAL: Central Register of Controlled Trials; RCT: randomised controlled
trial; PTB: pulmonary tuberculosis
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and sixty-nine patients received treatment, whilst 1271
were on identical placebo in addition to TB treatment.
Two thousand and fifty-seven participants contributed
data for the vitamin D treatment group whilst 483
participants contributed data for the other anti-
inflammatory agents group, for analysis of various study
outcomes. The treatment outcome endpoint measured,
ranged from 4 to 8 weeks, with follow-up duration up to
32 weeks. The age range of the 2540 participants in-
cluded in the meta-analysis was from 18 to 70 years in
both the intervention and control groups, and 1898
(74.7%) were male. Administration of treatment to par-
ticipants in the intervention arm was as follows: treat-
ment was administered at baseline only [23], daily [18,
25, 44, 47–49], twice a week [50], weekly then 2-weekly
[46], 2-weekly [15, 16, 21], 4-weekly [20], 3 times over a
period of 32 weeks (at baseline, 20 weeks and 32 weeks)
[45] and at baseline and 4 weeks [14]. Four hundred and
three (28.6%) of the 1411 participants in 11 studies [16,
20, 21, 23, 25, 44–48, 50] tested positive for HIV status
at baseline. The proportion of participants with MDR-
TB (i.e. their Mtb complex isolate was resistant to at
least isoniazid and rifampicin) was 3.9%, which is 57 out
of 1460 reported in 7 studies [15, 16, 18, 20, 21, 25, 46]
(Table 3).
Description of outcomes of included studies
Twelve studies reported the sputum smear conversion
rate [14–16, 18, 20, 21, 23, 44–50], whilst ten studies re-
ported the sputum culture conversion rate [15, 16, 18,
20, 21, 25, 46–48, 50]. Eleven reported the time to spu-
tum smear conversion [15, 18, 20, 21, 23, 25, 45, 47–50]
and eight provided the time to sputum culture conver-
sion [15, 16, 21, 25, 46–48, 50]. Six reported changes in
BMI [14–16, 21, 23, 44], four presented changes in mean
MUAC [14, 15, 23, 45], ten provided the data on chest
radiograph change [14, 15, 18, 20, 21, 25, 44, 46–49] and
five presented results on TB clinical score changes [14,
18, 20, 23, 45]. Eleven presented the incidence of adverse
events [15, 16, 18, 20, 21, 25, 45–48, 50], nine indicated
the changes in weight gain [14, 18, 20, 25, 45, 47–50],
eight provided the incidence of all-cause mortality [15,
16, 20, 21, 45–47, 50], four exhibited changes in CRP
and ESR [15, 18, 21, 23], and eight studies showed
changes in other blood parameters such as total white
cells, lymphocytes, neutrophils, monocytes and TNF-α
[15, 18, 21, 23, 25, 44, 47, 48, 50]. Details on study out-
come assessments are summarised in supplementary Ta-
bles 3 and 4 (Additional file 2).
Risk of bias and influence analysis across and within
studies
A funnel plot and Egger’s test for the outcome of rate of
sputum smear conversion across studies did suggest a
publication bias in trials involving vitamin D but not for
those involving other anti-inflammatory treatments, in
relation to this outcome (Additional file 2:Supplemen-
tary Figs. 1 & 2). An Egger’s test revealed an uneven
spread of results of RCTs skewed at one side of the over-
all adjusted hazard ratio as shown in Supplementary
Table 1 Characteristics of each trial included in meta-analysis
Author (year) Study setting (s) Trial registration Anti-TB therapy Type, dose and route of treatment
(intervention)
Martineau 2011 [21] UK NCT00419068 2 months HRZE Vit D3, 2.5 mg,oral
Daley 2015 [16] India NCT00366470 2 months HRZE Vit D3, 2.5 mg,oral
Farazi 2017 [36] Iran IRCT201407029855N5 2months HRZE then 4 months RH Vit D3,11.2 mg,intramuscular
Mily 2015 [18] Bangladesh NCT01580007 2 months HRZE then 4 months RH Vit D3,0.13 mg and PBA,500 mg,oral
Nursyam 2006 [37] Indonesia NM 2months HRZE then 4 months RH Vit D3, 0.25 mg,oral
Ralph 2013 [20] Indonesia NCT00677339 2 months HRZE then 4 months RH Vit D3,1.25 mg, and L-arginine,6 g,oral
Salahuddin 2013 [14] Pakistan NCT01130311 2 months HRZE, then6 months HE Vit D3,15 mg, intramuscular
Tukvadze 2015 [39] Georgia NCT00918086 2 months HRZE then 4 months RH Vit D3,1.25 mg, oral
Wejse 2009 [38] Guinea-Bissau ISRCTN35212132 2 months HRZE, then 6months HE Vita D3, 2.5 mg,oral
Johnson 2003 [40] Uganda NM 2months HRZE then 4 months RH rIL-2,11.2 mg,intradermal
Mayanja-Kizza 2005 [41] Uganda NM 2months HRZE then 4 months RH Prednisolone, 2.75 mg,oral
Pedral-Sampaio 2003 [44] Brazil NM 2months HRZ then 4months RH Rhu-GM-CSF,125 μg, subcutaneous
Willis 1996 [42] Ugandan NM 2months HRZ then 4months RH Pentoxifylline,1800 mg,oral
Mahakalkar 2017 [43] India not registered 2 months HRZ then 4months RH N-acetylcysteine,600 mg,oral
Ganmaa 2017 [15] Mongolia NCT01657656 2 months HRZE vit D3, 3.5 mg,oral
NM not mentioned, Vit Vitamins, HRZE isoniazid,rifampicin, pyrazinamide, ethambutol, RH rifampicin & isoniazid, HE isoniazid & ethambutol, mg milligram, μg
microgram, g gram, PBA phenylbutyrate, Rhu-GM-CSF recombinant human granulocyte-macrophage colony-stimulating factor, rIL recombinant human Interleukin,
UK United kingdom, Anti-TB Anti-tuberculosis, vit D3 vitamin D3
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Fig. 1. Seven RCTs [14, 15, 21, 25, 46–48] were at low
risk of bias for all aspects analysed according to the
Cochrane Collaboration Risk of Bias tool. The study led
by Nursyam and colleagues [44] had an unclear risk bias
due to selection bias (adequate sequence generation)
and detection bias (blinding). Methods used in random
sequence generation, blinding of participants, personnel
and outcome assessments were not clearly or adequately
described. Even though this could have affected the out-
come, no evidence was found that it did. Selection bias
was also observed in the trial by Pedral-Sampaio and
colleagues, as it did not adequately describe a clear
method used in random sequence generation [50]. RCTs
conducted by Daley, Mahakalkar, Mily, Wejse and Ralph
had an unclear risk of attrition bias due to incomplete
outcome data [16, 18, 20, 45, 49] as a result of relatively
high rates of loss to follow-up (LFU) of participants (>
20%). In addition, no evidence was found that it affected
the overall final outcome of these studies, since the LFU
was similar amongst groups. Some reasons for the LFU
common to these studies included defaulting, death or
transfer of patients to other locations of residence or for
treatment. Details on the risk of bias assessment are pro-
vided in supplementary Table 2 (Additional file 2).
There was a low statistical heterogeneity observed be-
tween/within treatments using other anti-inflammatory
agents (I2 = 11.2%, p = 0.342), compared to the vitamin
D supplementation group (I2 = 69.5%, p = 0.006) in the
proportion of the rate of sputum smear conversion
(Fig. 2 & Fig. 3). The high heterogeneity observed in the
vitamin D supplementation group could be as a result of
the different adjunct treatment doses administered, tim-
ing (Table 1) or duration of treatment (Table 3). The ex-
clusion of the study from Salahuddin et al. [14] reduced
the between-study heterogeneity to 53.3%. Overall, influ-
ence analysis did not detect any relevant difference in
the relative risk (RR) estimate when excluding single
studies. Likewise, no study was excluded due to dubious
decisions as a result of the sensitivity analysis conducted
to exclude any study.
Primary outcome
The results represent the sputum smear conversion rate
upon HDT treatment measured after a period of 4–8
weeks. It was observed that there was a 38% increased
rate of sputum smear negativity among patients adminis-
tered with vitamin D, compared to those receiving only
the TB treatment (RR 1.38, 95% CI 1.03 to 1.84). There
was moderate to high between-study heterogeneity ob-
served in this group (p = 0.006 and I2 = 69.5%) (Fig. 2).
Similarly, patients treated with other anti-inflammatory
HDT agents had a 29% increased sputum smear conver-
sion rate (RR 1.29, 95% CI 1.09 to 1.53). No heterogen-
eity was observed between studies in this group (p =
0.342 and I2 = 11.2%) (Fig. 3).
Secondary outcomes
Sputum smear and culture time to conversion tended to
be faster in the treatment group than in placebo in both
vitamin D and other anti-inflammatory adjunct therapies
in general. However, the sputum culture conversion rate
at 8 weeks did not differ significantly and was similar
Fig. 2 Forest plot of the random and fixed effect estimates of sputum smear conversion rate in vitamin D supplemented randomized controlled
trials. CI: confidence interval; RR: relative riskNB: Weights are from random effects analysis.
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between groups in the majority of trials. Administration
of vitamin D did not influence the proportion of partici-
pants with sputum culture conversion at 8 weeks (treat-
ment vs placebo, 150 of 190 vs. 148 of 200, respectively;
adjusted odds ratio, 1.47; 95% CI, 0.88–2.45; P = 0.14).
However, vitamin D did significantly accelerate sputum
smear conversion (adjusted HR, 1.47; 95% CI,1.09–1.98)
more in the treatment arm according to Ganmaa et al.
[15] (Supplementary Table 4a).
Similarly, higher sputum clearance in the treatment
group were reported by Farazi et al. (OR 0.20, 95% CI
0.04–1.02; p = 0.037) [23], Nursyam et al. (p = 0.002)
[44] and Mayanja-Kizza et al. [47]. The proportion of
participants with negative sputum culture at 4 weeks was
significantly different for those randomised to vitamin D
versus placebo (62% vs 37%, p = 0.001) but not at week
8 [47]. Mily et al. reported similar observations (OR
3.37, 95% CI 1.0–10.8; p = 0.041) [18]. According to
Mahakalkar et al., there was a significant clearing of in-
filtration and reduction in cavity size in treatment com-
pared to placebo (87.5% vs 33.33%, p < 0.05) and (p <
0.01) at 8 weeks, respectively [49]. Ganmaa et al. also re-
ported vitamin D accelerated radiographic resolution
(mean number of zones affected on chest radiograph at
8 weeks, treatment vs placebo, 5.48 vs 5.69 respectively;
95% CI for difference, − 0.06–0.77 zones; p = 0.02) [15].
There was also a 50% reduction in cavity size observed
in the vitamin D arm compared to the placebo arm (p =
0.035) [14]. Most trials, however, did not observe signifi-
cant clearing of infiltration or reduction in cavity size in
treatment compared to placebo groups (Supplementary
Table 4a).
There was no clinically significant difference in the
change in MUAC between the vitamin D treatment and
placebo group according to Salahuddin et al. [14]. How-
ever, Ganmaa et al. observed changes in MAUC after 8
weeks of treatment (adjusted mean difference,0.25,95%
CI 0.08–0.43; p = 0.04) [15]. No significant effect was ob-
served on concentrations of CRP and ESR at 8 weeks in
three reported vitamin D supplemented trials [15, 18,
21]. However, an increase in CRP was seen in the pla-
cebo group at the end of 4 weeks (OR 2.98, 95% CI
1.04–8.52; p = 0.038) and 8 weeks (OR 3.33, 95% CI 1–
11.14; p = 0.044) of treatment [23]. In addition, the ESR
was observed to be higher in the placebo group com-
pared to the Vitamin D group though not significantly
(Vitamin D vs placebo, 33.5 ± 22.0 vs 36.3 ± 22.2 respect-
ively) [18]. Similarly, there were no major significant ef-
fects of supplementary treatments observed with regards
to weight gain and BMI for some of the vitamin D and
other anti-inflammatory treatment groups. However,
Salahuddin et al., Daley et al., and Mahakalkar et al. [14,
16, 49] reported highly significant weight changes in the
vitamin D and N-acetylcysteine treatment groups com-
pared to the placebo groups (3.75 vs 2.61; p < 0.009, 3·1;
p < 0·0001, and 2.66 ± 0.18 vs − 0.02 ± 0.03; p < 0.001, re-
spectively). Farazi et al. [23] also found marginal signifi-
cant changes in BMI in favour of the vitamin D
treatment group (24.66 ± 4.3 vs 22.31 ± 3.9, 95% CI
0.23–4.47) in comparison to Daley et al. [16], who
Fig. 3 Forest plot of the random and fixed effect estimates of sputum smear conversion rate in other anti-inflammatory agents supplemented
randomized controlled trials. CI: confidence interval; RR: relative risk
Hayford et al. Respiratory Research          (2020) 21:223 Page 10 of 14
observed increased BMI changes in favour of placebo
group (0·087 kg/m2, p = 0·597) (Supplemetary Table 4b).
Changes in time to clinical improvement of the TB
score were also similar in the two groups in three re-
ported vitamin D supplemented trials included in this
review. Farazi and colleagues [23], however, showed that
the vitamin D group had a low TB score and better
health related quality of life in comparison to placebo
after 8 weeks of treatment (2.4 ± 1.5 vs 3.7 ± 1.7 95% CI
-2.13 -- 0.47; p = 0.003 and 52.3 ± 9.6 vs 46.2 ± 10.1; p =
0.019, respectively). Adverse effects (AEs) were reported
in the majority of the studies and there were no differ-
ences in the occurrence of most of the AEs between the
study arms. However, in the study by Johnson et al.,
hyperpigmentation (recombinant human Interleukin vs
placebo, 55 vs 1; p < 0.0001) and other adverse effects
were observed to be higher in the treatment group [25].
No study reported mortality due to study intervention
except for the study by Mayanja-Kizza et al. (prednisol-
one vs placebo, 17 vs 14 respectively; p = 0.28) [47]. Two
studies reported that vitamin D administration was asso-
ciated with reduced total white blood cell counts, neu-
trophil counts and monocyte counts [15, 21]. The
lymphocyte to monocyte ratio was significantly higher in
the intervention than in the control group at 8 weeks
(3.52 vs 2.70, 95% CI for difference 0.16–1.11; p = 0.009)
[21] and adjusted mean difference 0.4, 95% CI 0.2–0.6;
p = 0.001 [15]. The median levels of TNF-α decreased by
at least 50% from baseline values in the treatment arm
compared to the placebo at 4 weeks (p < 0.001) [47].
There was a similar trend toward reduced TNF-α pro-
duction in the pentoxifylline arm, although the differ-
ence between groups was not statistically significant
(pentoxifylline vs placebo,0.4 vs 0.6 respectively; p =
0.27) [48] (Supplementary Table 4c)..
Discussion
Sputum smear or culture conversion rate is a key bio-
marker used to predict TB cure. This biomarker has
been found to be directly associated with relapse risk
when regimens of equal duration were compared, and
patients were on a modern short-course TB regimen
[33, 51, 52]. The results of this systematic review and
meta-analysis revealed that there was a faster sputum
smear conversation rate among patients on adjunct ther-
apy, compared to those on placebo between 4 and 8
weeks of anti-TB treatment. This finding was consistent
with a meta-analysis published by Jingyan et al. in 2014
[31], which indicated that patients on vitamin D supple-
mentation were at a reduced risk of remaining sputum
positive after 6 weeks of anti-TB treatment compared to
those in the control group, though not statistically sig-
nificant. The non-significant effect observed in Jingyan’s
study could be as a result of the limited number of trials
included in the meta-analysis. Similar trends of non-
significant sputum smear conversion rate changes were
also observed from the results of other existing system-
atic reviews and aggregate data meta-analyses [30, 53,
54]. However, results from a meta-analysis of individual
participant data from eight RCTs of adjunctive vitamin
D in patients with PTB by Jolliffe et al. [6], which indi-
cated a modestly accelerated sputum smear conversion
rate in the treatment group, was consistent with our
results.
The proportion of sputum smear or culture negativity
did not differ significantly between groups across most
of the trials, even though sputum smear or culture
tended to convert to negative faster in the treatment
group than in the placebo group. A similar trend was
observed in the meta-analysis by Jolliffe et al. [6] and
Riaz et al. [32], but not by Wu et al. [30] in the vitamin
D supplemented group. Even though Wu at el [30]. re-
ported significant differences in the overall effect in the
proportion of sputum smear or culture conversion
among the two study arms, no difference was observed
between 4 and 8 weeks of treatment. This could be as a
result of fewer studies included in the meta-analysis. Ad-
ministration of daily prednisolone, given together with
standard TB drug therapy, also reduced the proportion
of positive cultures at 8 weeks from 15 to 2% according
to Wallis [17].
Adverse effects observed in all the trials were deemed
‘unlikely to be related’ to study medications, as there
were no differences in their occurrence between the
study arms. There was no difference in adverse effect
and mortality reported between the study arms for all
adjunct treatments administered in the included studies,
demonstrating the safety of their use. This finding was
in accordance with previously reported systematic re-
views and meta-analysis previously mentioned [30, 31].
Though there were some adverse effects such as hyper-
pigmentation, pain at injection site and erythema as a re-
sult of recombinant human interlukin administration,
they were mild to moderate in severity and the duration
was short. None of the subjects had to discontinue or re-
quired dose reduction as a result of these side effects, as
the interlukin was generally well-tolerated. Also, even
though Mayanja-Kizza et al. [47] reported mortality in
the prednisolone arm of the study, only 1 was classified
as probably related and 2 were classified as possibly re-
lated to the study intervention. There was no difference
in short-term survival between the intervention and pla-
cebo arms. Notwithstanding, Critchley et al. indicated
that corticosteroids could be effective in reducing mor-
tality in persons with pulmonary tuberculosis, though
more evidence is needed [55].
There was also limited evidence observed for the dif-
ference in changes in time to clinical improvement with
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regards to chest radiograph, MUAC, weight gain or BMI
changes, and the overall TB score between the treatment
and control groups. However, significant improvement
of chest radiographs was observed between study arms
in favour of the treatment group, where vitamin D and
N-acetylcysteine were administered [15, 49], which was
consistent with the findings of Wu et al. [30]. However,
considering the limited number of studies that reported
this outcome, more studies are required to either con-
firm this observation or not. Results on weight gain be-
tween the two study arms were consistent with other
reported studies [30, 31].
Although no significant effect of improvement was ob-
served in either group in the concentrations of CRP and
ESR, which are biomarkers of inflammation [56, 57], the
lymphocyte to monocyte ratio was shown to be signifi-
cantly higher in the intervention administered with vita-
min D than in the control group [15, 21]. This marker is
a recognised biomarker of resolution of pulmonary in-
flammation in human and animal TB models [19, 58]. A
trend toward reduced TNF-α production was also ob-
served in participants treated with adjunctive prednisol-
one and pentoxifylline treatments. Pentoxifylline has
been shown to suppress the synthesis of TNF—α from
lipopolysaccharide-stimulated (LPS) human monocytes
in cell cultures [59], inhibits LPS-induced TNF—α pro-
duction from peripheral blood monocytes and alveolar
macrophages, and can also inhibit the spontaneous
TNF-α production [60]. Tumour necrosis factor-α is es-
sential for immune control of infection with Mtb but
has the potential to cause severe tissue damage [61, 62].
The positive effect of these adjunct treatments may yet
play a critical role in improving lung function by the end
of the TB treatment. It is possible that, by reducing lung
inflammation, these adjunct treatments may improve
drug penetration into affected tissue; thereby accelerat-
ing the response to standard TB drug therapy [19]. This
may warrant additional studies to test this hypothesis.
This meta-analysis is different from most previously
reported in that we included the most RCTs in the field
of HDT adjunct treatment of TB, which were double-
blinded and placebo-controlled. Secondly, it also in-
cluded other adjunct treatments such as pentoxifylline,
N-acetylcysteine and prednisolone, instead of vitamin D
alone, which has been the focus of previously reported
meta-analysis. Besides reporting the sputum conversion,
which is an important indicator of treatment efficacy
and success [63, 64], this meta-analysis also focused on
the anti-inflammatory property of these treatment
agents. This immunomodulatory property (effect) may
have the potential of reducing residual lung damage,
which is common after TB antimicrobial therapy and
needs to be further investigated in a phase 2 or 3 clinical
trial.
There are some limitations of this study: firstly, im-
munological characteristics were only determined in a
minority of the studies, therefore,their immunomodula-
tory effect in TB should be further investigated to in-
clude more TB sensitive inflammatory biomarkers to
confirm these potential properties. Secondly, the dose,
timing and duration of treatment in both the vitamin D
group and the other anti-inflammatory agents were dif-
ferent and not standardised. This could have influenced
the results to some extent, such as the increased hetero-
geneity observed among the vitamin adjunct treatment.
Thus, the need to standardise the dosing and also opti-
mise the schedule of administration is vital for future
clinical trials. Interpretation of the funnel plot in the
vitamin D supplemented group indicated publication
bias. This could be attributed to the number of studies
included in the group, which may have influenced the
results.
Conclusion
In summary, this meta-analysis found that adjunctive
treatment with vitamin D, pentoxifylline, N-acetylcysteine,
prednisolone, recombinant human Interleukin and Rhu-
GM-CSF may be a well-tolerated and effective addition to
the treatment of TB patients. They were shown to signifi-
cantly improve sputum conversion, chest radiographs ap-
pearance and also exhibit inflammation resolution
properties. Thus, supplementing pulmonary TB patients
on standard drug treatment with these HDT adjunct ther-
apies may be justified. Also, considering the major eco-
nomic burden associated with PTB, the use of low-cost
adjunctive therapy such as vitamin D and pentoxifylline
for such intervention could be regarded as cost-effective.
However, future RCTs need to standardise the doses of
these adjunct treatments and also optimise the schedule
of administration. Secondly, more studies need to include
more TB sensitive inflammatory biomarkers as an out-
come measure, since resolution of inflammatory responses
during TB therapy is associated with reducing high mor-
tality in TB.
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